| 29 | | - | SECTION 1. AMENDATORY 63 O.S. 2021, Section 2-309I, is |
|---|
| 173 | + | ENGR. H. B. NO. 3073 Page 2 1 |
|---|
| 174 | + | 2 |
|---|
| 175 | + | 3 |
|---|
| 176 | + | 4 |
|---|
| 177 | + | 5 |
|---|
| 178 | + | 6 |
|---|
| 179 | + | 7 |
|---|
| 180 | + | 8 |
|---|
| 181 | + | 9 |
|---|
| 182 | + | 10 |
|---|
| 183 | + | 11 |
|---|
| 184 | + | 12 |
|---|
| 185 | + | 13 |
|---|
| 186 | + | 14 |
|---|
| 187 | + | 15 |
|---|
| 188 | + | 16 |
|---|
| 189 | + | 17 |
|---|
| 190 | + | 18 |
|---|
| 191 | + | 19 |
|---|
| 192 | + | 20 |
|---|
| 193 | + | 21 |
|---|
| 194 | + | 22 |
|---|
| 195 | + | 23 |
|---|
| 196 | + | 24 |
|---|
| 197 | + | |
|---|
| 198 | + | a. a practitioner (or, in the presence of the |
|---|
| 199 | + | practitioner, by the authorize d agent of the |
|---|
| 200 | + | practitioner), or |
|---|
| 201 | + | b. the patient or research subject at the direction and |
|---|
| 202 | + | in the presence of the prac titioner; |
|---|
| 203 | + | 2. "Agent" means a peace officer appointe d by and who acts on |
|---|
| 204 | + | behalf of the Director of the Oklahoma State Bureau of Narcotics an d |
|---|
| 205 | + | Dangerous Drugs Cont rol or an authorized person who acts on behalf |
|---|
| 206 | + | of or at the direction of a person who manufact ures, distributes, |
|---|
| 207 | + | dispenses, prescribes, administer s or uses for scientific purposes |
|---|
| 208 | + | controlled dangerous substances but does not include a common or |
|---|
| 209 | + | contract carrier, public warehouser or employee thereof, or a pe rson |
|---|
| 210 | + | required to register under the Unifo rm Controlled Dangerous |
|---|
| 211 | + | Substances Act; |
|---|
| 212 | + | 3. "Board" means the Advisory Board to the Direc tor of the |
|---|
| 213 | + | Oklahoma State Bureau of Narcotics and D angerous Drugs Control ; |
|---|
| 214 | + | 4. "Bureau" means the Oklahoma State Bureau of Nar cotics and |
|---|
| 215 | + | Dangerous Drugs Control; |
|---|
| 216 | + | 5. "Coca leaves" includes cocaine and any compound, |
|---|
| 217 | + | manufacture, salt, derivative, mixture or preparation of coca |
|---|
| 218 | + | leaves, except derivatives of coca leaves which do n ot contain |
|---|
| 219 | + | cocaine or ecgonine; |
|---|
| 220 | + | 6. "Commissioner" or "Director" means the Director of the |
|---|
| 221 | + | Oklahoma State Bureau of Narcotics and Dangerous Drugs Control; |
|---|
| 222 | + | |
|---|
| 223 | + | ENGR. H. B. NO. 3073 Page 3 1 |
|---|
| 224 | + | 2 |
|---|
| 225 | + | 3 |
|---|
| 226 | + | 4 |
|---|
| 227 | + | 5 |
|---|
| 228 | + | 6 |
|---|
| 229 | + | 7 |
|---|
| 230 | + | 8 |
|---|
| 231 | + | 9 |
|---|
| 232 | + | 10 |
|---|
| 233 | + | 11 |
|---|
| 234 | + | 12 |
|---|
| 235 | + | 13 |
|---|
| 236 | + | 14 |
|---|
| 237 | + | 15 |
|---|
| 238 | + | 16 |
|---|
| 239 | + | 17 |
|---|
| 240 | + | 18 |
|---|
| 241 | + | 19 |
|---|
| 242 | + | 20 |
|---|
| 243 | + | 21 |
|---|
| 244 | + | 22 |
|---|
| 245 | + | 23 |
|---|
| 246 | + | 24 |
|---|
| 247 | + | |
|---|
| 248 | + | 7. "Control" means to add, remove or change the placement of a |
|---|
| 249 | + | drug, substance or immediate precurso r under the Uniform Controlled |
|---|
| 250 | + | Dangerous Substances A ct; |
|---|
| 251 | + | 8. "Controlled dangerous substance " means a drug, substance or |
|---|
| 252 | + | immediate precursor in Sc hedules I through V of the Uniform |
|---|
| 253 | + | Controlled Dangerous Substances Act or any drug, subs tance or |
|---|
| 254 | + | immediate precursor listed either temporarily or permanently as a |
|---|
| 255 | + | federally controlled substance . Any conflict between state and |
|---|
| 256 | + | federal law with regard to th e particular schedule in which a |
|---|
| 257 | + | substance is listed shall be resolved in favor of state law; |
|---|
| 258 | + | 9. "Counterfeit substance" means a controlled substance which, |
|---|
| 259 | + | or the container or labeling of which without authorization, bears |
|---|
| 260 | + | the trademark, trade name or ot her identifying marks, imprint, |
|---|
| 261 | + | number or device or any likeness thereof of a manufactur er, |
|---|
| 262 | + | distributor or dispenser other than the person who in fact |
|---|
| 263 | + | manufactured, distributed or dispensed the substance; |
|---|
| 264 | + | 10. "Deliver" or "delivery" means the actual, cons tructive or |
|---|
| 265 | + | attempted transfer from o ne person to another of a controlled |
|---|
| 266 | + | dangerous substance or drug parapher nalia, whether or not there is |
|---|
| 267 | + | an agency relationship ; |
|---|
| 268 | + | 11. "Dispense" means to deliver a cont rolled dangerous |
|---|
| 269 | + | substance to an ultimate user or h uman research subject by or |
|---|
| 270 | + | pursuant to the lawful order of a practitioner, including the |
|---|
| 271 | + | prescribing, administ ering, packaging, labeling or compounding |
|---|
| 272 | + | |
|---|
| 273 | + | ENGR. H. B. NO. 3073 Page 4 1 |
|---|
| 274 | + | 2 |
|---|
| 275 | + | 3 |
|---|
| 276 | + | 4 |
|---|
| 277 | + | 5 |
|---|
| 278 | + | 6 |
|---|
| 279 | + | 7 |
|---|
| 280 | + | 8 |
|---|
| 281 | + | 9 |
|---|
| 282 | + | 10 |
|---|
| 283 | + | 11 |
|---|
| 284 | + | 12 |
|---|
| 285 | + | 13 |
|---|
| 286 | + | 14 |
|---|
| 287 | + | 15 |
|---|
| 288 | + | 16 |
|---|
| 289 | + | 17 |
|---|
| 290 | + | 18 |
|---|
| 291 | + | 19 |
|---|
| 292 | + | 20 |
|---|
| 293 | + | 21 |
|---|
| 294 | + | 22 |
|---|
| 295 | + | 23 |
|---|
| 296 | + | 24 |
|---|
| 297 | + | |
|---|
| 298 | + | necessary to prepare the substance for such distribu tion. |
|---|
| 299 | + | "Dispenser" is a practitioner who delivers a controlled dangerous |
|---|
| 300 | + | substance to an ultimate user or human research subject; |
|---|
| 301 | + | 12. "Distribute" means to deliver other than by administering |
|---|
| 302 | + | or dispensing a contro lled dangerous substance; |
|---|
| 303 | + | 13. "Distributor" means a commercial entity engaged in the |
|---|
| 304 | + | distribution or reverse distribution of narc otics and dangerous |
|---|
| 305 | + | drugs and who complies with all regulations promulgat ed by the |
|---|
| 306 | + | federal Drug Enforcement Administration and the Oklahoma State |
|---|
| 307 | + | Bureau of Narcotics a nd Dangerous Drugs Control; |
|---|
| 308 | + | 14. "Drug" means articles: |
|---|
| 309 | + | a. recognized in the official Uni ted States Pharmacopeia, |
|---|
| 310 | + | official Homeopathic Pharm acopoeia of the United |
|---|
| 311 | + | States, or official National Formulary, or any |
|---|
| 312 | + | supplement to any of them, |
|---|
| 313 | + | b. intended for use in the diagnosis, cure, mitigation, |
|---|
| 314 | + | treatment or prevention of disease in man or other |
|---|
| 315 | + | animals, |
|---|
| 316 | + | c. other than food, intended to affect the structure or |
|---|
| 317 | + | any function of the body of man or other animals, and |
|---|
| 318 | + | d. intended for use as a component of any article |
|---|
| 319 | + | specified in this paragraph; |
|---|
| 320 | + | provided, however, the term "drug" does not include devices or their |
|---|
| 321 | + | components, parts or accessories; |
|---|
| 322 | + | |
|---|
| 323 | + | ENGR. H. B. NO. 3073 Page 5 1 |
|---|
| 324 | + | 2 |
|---|
| 325 | + | 3 |
|---|
| 326 | + | 4 |
|---|
| 327 | + | 5 |
|---|
| 328 | + | 6 |
|---|
| 329 | + | 7 |
|---|
| 330 | + | 8 |
|---|
| 331 | + | 9 |
|---|
| 332 | + | 10 |
|---|
| 333 | + | 11 |
|---|
| 334 | + | 12 |
|---|
| 335 | + | 13 |
|---|
| 336 | + | 14 |
|---|
| 337 | + | 15 |
|---|
| 338 | + | 16 |
|---|
| 339 | + | 17 |
|---|
| 340 | + | 18 |
|---|
| 341 | + | 19 |
|---|
| 342 | + | 20 |
|---|
| 343 | + | 21 |
|---|
| 344 | + | 22 |
|---|
| 345 | + | 23 |
|---|
| 346 | + | 24 |
|---|
| 347 | + | |
|---|
| 348 | + | 15. "Drug-dependent person" means a person who is using a |
|---|
| 349 | + | controlled dangerous su bstance and who is in a state of psychic or |
|---|
| 350 | + | physical dependence, or both, arising from administration of that |
|---|
| 351 | + | controlled dangerous substance on a continuous basis . Drug |
|---|
| 352 | + | dependence is characterized by be havioral and other responses which |
|---|
| 353 | + | include a strong compulsion to take the substance on a cont inuous |
|---|
| 354 | + | basis in order to experience its psychic effects, or to avoid the |
|---|
| 355 | + | discomfort of its absence; |
|---|
| 356 | + | 16. "Home care agency" means any sole proprietorship, |
|---|
| 357 | + | partnership, association, corporation, or other organization which |
|---|
| 358 | + | administers, offers, or provides h ome care services, for a fee or |
|---|
| 359 | + | pursuant to a contract for such services, to clients in t heir place |
|---|
| 360 | + | of residence; |
|---|
| 361 | + | 17. "Home care services" means skilled or perso nal care |
|---|
| 362 | + | services provided to clients in their place of residence for a fee; |
|---|
| 363 | + | 18. "Hospice" means a centrally administered, nonprofit or for- |
|---|
| 364 | + | profit, medically directed, nurse -coordinated program which provides |
|---|
| 365 | + | a continuum of home and inpatient care for the terminally ill |
|---|
| 366 | + | patient and the patient 's family. Such term shall also include a |
|---|
| 367 | + | centrally administered, nonprofit or for-profit, medically directed, |
|---|
| 368 | + | nurse-coordinated program if suc h program is licensed pursuant to |
|---|
| 369 | + | the provisions of the Uniform Controlle d Dangerous Substances Act . |
|---|
| 370 | + | A hospice program offers palliative and supportive care to meet t he |
|---|
| 371 | + | special needs arising out of the physical, emotional and spiritual |
|---|
| 372 | + | |
|---|
| 373 | + | ENGR. H. B. NO. 3073 Page 6 1 |
|---|
| 374 | + | 2 |
|---|
| 375 | + | 3 |
|---|
| 376 | + | 4 |
|---|
| 377 | + | 5 |
|---|
| 378 | + | 6 |
|---|
| 379 | + | 7 |
|---|
| 380 | + | 8 |
|---|
| 381 | + | 9 |
|---|
| 382 | + | 10 |
|---|
| 383 | + | 11 |
|---|
| 384 | + | 12 |
|---|
| 385 | + | 13 |
|---|
| 386 | + | 14 |
|---|
| 387 | + | 15 |
|---|
| 388 | + | 16 |
|---|
| 389 | + | 17 |
|---|
| 390 | + | 18 |
|---|
| 391 | + | 19 |
|---|
| 392 | + | 20 |
|---|
| 393 | + | 21 |
|---|
| 394 | + | 22 |
|---|
| 395 | + | 23 |
|---|
| 396 | + | 24 |
|---|
| 397 | + | |
|---|
| 398 | + | stresses which are experienced during the final stages of illness |
|---|
| 399 | + | and during dying and berea vement. This care is available twenty - |
|---|
| 400 | + | four (24) hours a day, seven (7) days a week, and is pr ovided on the |
|---|
| 401 | + | basis of need, regardless of ability to pay. "Class A" Hospice |
|---|
| 402 | + | refers to Medicare-certified hospices. "Class B" refers to all |
|---|
| 403 | + | other providers of h ospice services; |
|---|
| 404 | + | 19. "Imitation controlled substance " means a substance that is |
|---|
| 405 | + | not a controlled dangerous substance, which by dosage unit |
|---|
| 406 | + | appearance, color, shape, size, markings or by representations made, |
|---|
| 407 | + | would lead a reasonable p erson to believe that the substance is a |
|---|
| 408 | + | controlled dangerous substance . In the event the appearance of the |
|---|
| 409 | + | dosage unit is not reasonably sufficient to establish that the |
|---|
| 410 | + | substance is an "imitation controlled substance", the court or |
|---|
| 411 | + | authority concerned s hould consider, in add ition to all other |
|---|
| 412 | + | factors, the following factors as related to "representations made " |
|---|
| 413 | + | in determining whether the substance is an "imitation controlled |
|---|
| 414 | + | substance": |
|---|
| 415 | + | a. statements made by an owner or by any other person in |
|---|
| 416 | + | control of the substance concerning the nature of the |
|---|
| 417 | + | substance, or its use or effect, |
|---|
| 418 | + | b. statements made to the recipient that t he substance |
|---|
| 419 | + | may be resold for inordinate profit, |
|---|
| 420 | + | c. whether the substance is packaged in a manner normally |
|---|
| 421 | + | used for illicit controlled subs tances, |
|---|
| 422 | + | |
|---|
| 423 | + | ENGR. H. B. NO. 3073 Page 7 1 |
|---|
| 424 | + | 2 |
|---|
| 425 | + | 3 |
|---|
| 426 | + | 4 |
|---|
| 427 | + | 5 |
|---|
| 428 | + | 6 |
|---|
| 429 | + | 7 |
|---|
| 430 | + | 8 |
|---|
| 431 | + | 9 |
|---|
| 432 | + | 10 |
|---|
| 433 | + | 11 |
|---|
| 434 | + | 12 |
|---|
| 435 | + | 13 |
|---|
| 436 | + | 14 |
|---|
| 437 | + | 15 |
|---|
| 438 | + | 16 |
|---|
| 439 | + | 17 |
|---|
| 440 | + | 18 |
|---|
| 441 | + | 19 |
|---|
| 442 | + | 20 |
|---|
| 443 | + | 21 |
|---|
| 444 | + | 22 |
|---|
| 445 | + | 23 |
|---|
| 446 | + | 24 |
|---|
| 447 | + | |
|---|
| 448 | + | d. evasive tactics or actions utilized by the owner or |
|---|
| 449 | + | person in control of the substance to avoid detection |
|---|
| 450 | + | by law enforcement authorities, |
|---|
| 451 | + | e. prior convictions, if any, of an owner, or any other |
|---|
| 452 | + | person in control of the object, under state or |
|---|
| 453 | + | federal law related to co ntrolled substances or fraud, |
|---|
| 454 | + | and |
|---|
| 455 | + | f. the proximity of the substances to controlled |
|---|
| 456 | + | dangerous substances; |
|---|
| 457 | + | 20. "Immediate precursor" means a substance which the Director |
|---|
| 458 | + | has found to be and by regulation designates as being the princip al |
|---|
| 459 | + | compound commonly used or produced primarily for use, and which is |
|---|
| 460 | + | an immediate chemical intermediary used, or li kely to be used, in |
|---|
| 461 | + | the manufacture of a controlled dangerous substance, the control of |
|---|
| 462 | + | which is necessary to prevent, curtail or limit such manufacture; |
|---|
| 463 | + | 21. "Laboratory" means a laboratory approved by the Director as |
|---|
| 464 | + | proper to be entrusted with the custo dy of controlled dangerous |
|---|
| 465 | + | substances and the use of controlled dangerous substances for |
|---|
| 466 | + | scientific and medical purposes and for purposes of instruction; |
|---|
| 467 | + | 22. "Manufacture" means the production, preparation, |
|---|
| 468 | + | propagation, compounding or processing of a cont rolled dangerous |
|---|
| 469 | + | substance, either directly or indir ectly by extraction from |
|---|
| 470 | + | substances of natural or synthetic origin, or independently by means |
|---|
| 471 | + | of chemical synthesis or by a combination of extraction and chemical |
|---|
| 472 | + | |
|---|
| 473 | + | ENGR. H. B. NO. 3073 Page 8 1 |
|---|
| 474 | + | 2 |
|---|
| 475 | + | 3 |
|---|
| 476 | + | 4 |
|---|
| 477 | + | 5 |
|---|
| 478 | + | 6 |
|---|
| 479 | + | 7 |
|---|
| 480 | + | 8 |
|---|
| 481 | + | 9 |
|---|
| 482 | + | 10 |
|---|
| 483 | + | 11 |
|---|
| 484 | + | 12 |
|---|
| 485 | + | 13 |
|---|
| 486 | + | 14 |
|---|
| 487 | + | 15 |
|---|
| 488 | + | 16 |
|---|
| 489 | + | 17 |
|---|
| 490 | + | 18 |
|---|
| 491 | + | 19 |
|---|
| 492 | + | 20 |
|---|
| 493 | + | 21 |
|---|
| 494 | + | 22 |
|---|
| 495 | + | 23 |
|---|
| 496 | + | 24 |
|---|
| 497 | + | |
|---|
| 498 | + | synthesis. "Manufacturer" includes any person who packages, |
|---|
| 499 | + | repackages or labels any contain er of any controlled dangerous |
|---|
| 500 | + | substance, except practitioners who dispense or compound |
|---|
| 501 | + | prescription orders fo r delivery to the ultimate consumer; |
|---|
| 502 | + | 23. "Marijuana" means all parts of the plant Cannabis sa tiva |
|---|
| 503 | + | L., whether growing or not; the seeds thereof; the resin extracted |
|---|
| 504 | + | from any part of such plant; and every compound, manufacture, salt, |
|---|
| 505 | + | derivative, mixture or preparation of such plant, its seeds or |
|---|
| 506 | + | resin, but shall not include: |
|---|
| 507 | + | a. the mature stalks of such plant or fiber produced from |
|---|
| 508 | + | such stalks, |
|---|
| 509 | + | b. oil or cake made from the seeds of suc h plant, |
|---|
| 510 | + | including cannabidiol derived from the see ds of the |
|---|
| 511 | + | marijuana plant, |
|---|
| 512 | + | c. any other compound, manufacture, salt, deriva tive, |
|---|
| 513 | + | mixture or preparation of such matu re stalks (except |
|---|
| 514 | + | the resin extracted therefrom), in cluding cannabidiol |
|---|
| 515 | + | derived from mature stalks, fiber, oil or cake, |
|---|
| 516 | + | d. the sterilized seed of such plant which is incapable |
|---|
| 517 | + | of germination, |
|---|
| 518 | + | e. for any person parti cipating in a clinical trial to |
|---|
| 519 | + | administer cannabidiol for the treatment of severe |
|---|
| 520 | + | forms of epilepsy pursuant to Section 2 -802 of this |
|---|
| 521 | + | title, a drug or substance approved by the fed eral |
|---|
| 522 | + | |
|---|
| 523 | + | ENGR. H. B. NO. 3073 Page 9 1 |
|---|
| 524 | + | 2 |
|---|
| 525 | + | 3 |
|---|
| 526 | + | 4 |
|---|
| 527 | + | 5 |
|---|
| 528 | + | 6 |
|---|
| 529 | + | 7 |
|---|
| 530 | + | 8 |
|---|
| 531 | + | 9 |
|---|
| 532 | + | 10 |
|---|
| 533 | + | 11 |
|---|
| 534 | + | 12 |
|---|
| 535 | + | 13 |
|---|
| 536 | + | 14 |
|---|
| 537 | + | 15 |
|---|
| 538 | + | 16 |
|---|
| 539 | + | 17 |
|---|
| 540 | + | 18 |
|---|
| 541 | + | 19 |
|---|
| 542 | + | 20 |
|---|
| 543 | + | 21 |
|---|
| 544 | + | 22 |
|---|
| 545 | + | 23 |
|---|
| 546 | + | 24 |
|---|
| 547 | + | |
|---|
| 548 | + | Food and Drug Administration for use by those |
|---|
| 549 | + | participants, |
|---|
| 550 | + | f. for any person or the parents, legal guardians o r |
|---|
| 551 | + | caretakers of the person who have received a writt en |
|---|
| 552 | + | certification from a physician lic ensed in this state |
|---|
| 553 | + | that the person has been diagno sed by a physician as |
|---|
| 554 | + | having Lennox-Gastaut syndrome, Dravet syndrome, also |
|---|
| 555 | + | known as severe myoclonic epilepsy of i nfancy, or any |
|---|
| 556 | + | other severe form of epilepsy that is not adequately |
|---|
| 557 | + | treated by traditional medical therapies, spasticity |
|---|
| 558 | + | due to multiple scle rosis or due to parapl egia, |
|---|
| 559 | + | intractable nausea and vomiting, appetite stimu lation |
|---|
| 560 | + | with chronic wasting diseases, the substance |
|---|
| 561 | + | cannabidiol, a nonpsychoactive cannabinoi d, found in |
|---|
| 562 | + | the plant Cannabis sativa L. or any other preparation |
|---|
| 563 | + | thereof, that has a te trahydrocannabinol con centration |
|---|
| 564 | + | of not more than three -tenths of one percent (0.3%) |
|---|
| 565 | + | and that is delivered to the pa tient in the form of a |
|---|
| 566 | + | liquid, |
|---|
| 567 | + | g. any federal Food-and-Drug-Administration-approved drug |
|---|
| 568 | + | or substance, or |
|---|
| 569 | + | h. industrial hemp, from the plant Cannabis sativa L. an d |
|---|
| 570 | + | any part of such plant, whether growing or not, wit h a |
|---|
| 571 | + | delta-9 tetrahydrocannabinol concentr ation of not more |
|---|
| 572 | + | |
|---|
| 573 | + | ENGR. H. B. NO. 3073 Page 10 1 |
|---|
| 574 | + | 2 |
|---|
| 575 | + | 3 |
|---|
| 576 | + | 4 |
|---|
| 577 | + | 5 |
|---|
| 578 | + | 6 |
|---|
| 579 | + | 7 |
|---|
| 580 | + | 8 |
|---|
| 581 | + | 9 |
|---|
| 582 | + | 10 |
|---|
| 583 | + | 11 |
|---|
| 584 | + | 12 |
|---|
| 585 | + | 13 |
|---|
| 586 | + | 14 |
|---|
| 587 | + | 15 |
|---|
| 588 | + | 16 |
|---|
| 589 | + | 17 |
|---|
| 590 | + | 18 |
|---|
| 591 | + | 19 |
|---|
| 592 | + | 20 |
|---|
| 593 | + | 21 |
|---|
| 594 | + | 22 |
|---|
| 595 | + | 23 |
|---|
| 596 | + | 24 |
|---|
| 597 | + | |
|---|
| 598 | + | than three-tenths of one percent ( 0.3%) on a dry |
|---|
| 599 | + | weight basis which sha ll only be grown pursuant to the |
|---|
| 600 | + | Oklahoma Industrial Hemp Program and may be shipped |
|---|
| 601 | + | intrastate and interstate; |
|---|
| 602 | + | 24. "Medical purpose" means an intention to utilize a |
|---|
| 603 | + | controlled dangerous substance for physical or menta l treatment, for |
|---|
| 604 | + | diagnosis, or for th e prevention of a disease condition not in |
|---|
| 605 | + | violation of any state or fede ral law and not for the purpose of |
|---|
| 606 | + | satisfying physiological or psychological dependence or oth er abuse; |
|---|
| 607 | + | 25. "Mid-level practitioner" means an Advanced Practice |
|---|
| 608 | + | Registered Nurse as de fined and within parameters specified in |
|---|
| 609 | + | Section 567.3a of Title 59 of th e Oklahoma Statutes, or a certified |
|---|
| 610 | + | animal euthanasia technician as defined in Section 698.2 o f Title 59 |
|---|
| 611 | + | of the Oklahoma Statutes, or an animal co ntrol officer registered by |
|---|
| 612 | + | the Oklahoma State Bureau of Narcotics and Dangerous Drugs C ontrol |
|---|
| 613 | + | under subsection B of Section 2-301 of this title within the |
|---|
| 614 | + | parameters of such officer's duties under Sections 501 through 508 |
|---|
| 615 | + | of Title 4 of the Oklahoma Statut es; |
|---|
| 616 | + | 26. "Narcotic drug" means any of the following, whether |
|---|
| 617 | + | produced directly or indire ctly by extraction fro m substances of |
|---|
| 618 | + | vegetable origin, or independently by means of chemical synthesis, |
|---|
| 619 | + | or by a combination of extraction and chemical synthesis: |
|---|
| 620 | + | a. opium, coca leaves and opiates, |
|---|
| 621 | + | |
|---|
| 622 | + | ENGR. H. B. NO. 3073 Page 11 1 |
|---|
| 623 | + | 2 |
|---|
| 624 | + | 3 |
|---|
| 625 | + | 4 |
|---|
| 626 | + | 5 |
|---|
| 627 | + | 6 |
|---|
| 628 | + | 7 |
|---|
| 629 | + | 8 |
|---|
| 630 | + | 9 |
|---|
| 631 | + | 10 |
|---|
| 632 | + | 11 |
|---|
| 633 | + | 12 |
|---|
| 634 | + | 13 |
|---|
| 635 | + | 14 |
|---|
| 636 | + | 15 |
|---|
| 637 | + | 16 |
|---|
| 638 | + | 17 |
|---|
| 639 | + | 18 |
|---|
| 640 | + | 19 |
|---|
| 641 | + | 20 |
|---|
| 642 | + | 21 |
|---|
| 643 | + | 22 |
|---|
| 644 | + | 23 |
|---|
| 645 | + | 24 |
|---|
| 646 | + | |
|---|
| 647 | + | b. a compound, manufacture, salt, derivative or |
|---|
| 648 | + | preparation of opium, coca leave s or opiates, |
|---|
| 649 | + | c. cocaine, its salts, optical and geom etric isomers, and |
|---|
| 650 | + | salts of isomers, |
|---|
| 651 | + | d. ecgonine, its derivatives, their salts, isomers and |
|---|
| 652 | + | salts of isomers, and |
|---|
| 653 | + | e. a substance, and any compound, manufacture, salt, |
|---|
| 654 | + | derivative or preparation thereof, w hich is chemically |
|---|
| 655 | + | identical with any of the substanc es referred to in |
|---|
| 656 | + | subparagraphs a through d of this paragraph, except |
|---|
| 657 | + | that the words "narcotic drug" as used in Section 2 - |
|---|
| 658 | + | 101 et seq. of this title shall not include |
|---|
| 659 | + | decocainized coca leaves or extracts of coca leaves, |
|---|
| 660 | + | which extracts do not contain cocaine or ecgonine; |
|---|
| 661 | + | 27. "Opiate" or "opioid" means any Schedule II, III, IV or V |
|---|
| 662 | + | substance having an addiction-forming or addiction -sustaining |
|---|
| 663 | + | liability similar to morphine or being capa ble of conversion into a |
|---|
| 664 | + | drug having such addiction -forming or addiction -sustaining |
|---|
| 665 | + | liability. The terms do not inc lude, unless specifically designated |
|---|
| 666 | + | as controlled under the Uniform Controlled Dangerous Substances Act, |
|---|
| 667 | + | the dextrorotatory isomer of 3 -methoxy-n-methyl-morphinan and its |
|---|
| 668 | + | salts (dextromethorphan) . The terms do include the racemic and |
|---|
| 669 | + | levorotatory forms; |
|---|
| 670 | + | |
|---|
| 671 | + | ENGR. H. B. NO. 3073 Page 12 1 |
|---|
| 672 | + | 2 |
|---|
| 673 | + | 3 |
|---|
| 674 | + | 4 |
|---|
| 675 | + | 5 |
|---|
| 676 | + | 6 |
|---|
| 677 | + | 7 |
|---|
| 678 | + | 8 |
|---|
| 679 | + | 9 |
|---|
| 680 | + | 10 |
|---|
| 681 | + | 11 |
|---|
| 682 | + | 12 |
|---|
| 683 | + | 13 |
|---|
| 684 | + | 14 |
|---|
| 685 | + | 15 |
|---|
| 686 | + | 16 |
|---|
| 687 | + | 17 |
|---|
| 688 | + | 18 |
|---|
| 689 | + | 19 |
|---|
| 690 | + | 20 |
|---|
| 691 | + | 21 |
|---|
| 692 | + | 22 |
|---|
| 693 | + | 23 |
|---|
| 694 | + | 24 |
|---|
| 695 | + | |
|---|
| 696 | + | 28. "Opium poppy" means the plant of the species Pa paver |
|---|
| 697 | + | somniferum L., except the seeds thereof; |
|---|
| 698 | + | 29. "Palliative care" means patient-centered and family-focused |
|---|
| 699 | + | medical care that optimizes quality of life by anti cipating, |
|---|
| 700 | + | preventing, and treating suffer ing caused by a medical illness or a |
|---|
| 701 | + | physical injury or condition that substantially affe cts the quality |
|---|
| 702 | + | of life of a patient . Palliative care includes, but is not limited |
|---|
| 703 | + | to: |
|---|
| 704 | + | a. addressing physical, emotional, social, and spiritual |
|---|
| 705 | + | needs, |
|---|
| 706 | + | b. facilitating patient autonomy and choice of care, |
|---|
| 707 | + | c. providing access to information, |
|---|
| 708 | + | d. discussing the goals of treatment for the patient and |
|---|
| 709 | + | treatment options including, wh en appropriate, hospice |
|---|
| 710 | + | care, and |
|---|
| 711 | + | e. managing pain and symptoms comprehensively. |
|---|
| 712 | + | Palliative care does not always include a requirement for hospice |
|---|
| 713 | + | care or attention to sp iritual needs; |
|---|
| 714 | + | 30. "Peace officer" means a police officer, sher iff, deputy |
|---|
| 715 | + | sheriff, district attorney's investigator, investigator from th e |
|---|
| 716 | + | Office of the Attorney General, or any other person elected or |
|---|
| 717 | + | appointed by law to enforce any of the criminal laws of this state |
|---|
| 718 | + | or of the United States; |
|---|
| 719 | + | |
|---|
| 720 | + | ENGR. H. B. NO. 3073 Page 13 1 |
|---|
| 721 | + | 2 |
|---|
| 722 | + | 3 |
|---|
| 723 | + | 4 |
|---|
| 724 | + | 5 |
|---|
| 725 | + | 6 |
|---|
| 726 | + | 7 |
|---|
| 727 | + | 8 |
|---|
| 728 | + | 9 |
|---|
| 729 | + | 10 |
|---|
| 730 | + | 11 |
|---|
| 731 | + | 12 |
|---|
| 732 | + | 13 |
|---|
| 733 | + | 14 |
|---|
| 734 | + | 15 |
|---|
| 735 | + | 16 |
|---|
| 736 | + | 17 |
|---|
| 737 | + | 18 |
|---|
| 738 | + | 19 |
|---|
| 739 | + | 20 |
|---|
| 740 | + | 21 |
|---|
| 741 | + | 22 |
|---|
| 742 | + | 23 |
|---|
| 743 | + | 24 |
|---|
| 744 | + | |
|---|
| 745 | + | 30. 31. "Person" means an individual, corpora tion, government |
|---|
| 746 | + | or governmental subdivision or agenc y, business trust, estate, |
|---|
| 747 | + | trust, partnership or association, or any other legal entity; |
|---|
| 748 | + | 31. 32. "Poppy straw" means all parts, except the seeds , of the |
|---|
| 749 | + | opium poppy, after mowing; |
|---|
| 750 | + | 32. 33. "Practitioner" means: |
|---|
| 751 | + | a. (1) a medical doctor or osteopathic physi cian, |
|---|
| 752 | + | (2) a dentist, |
|---|
| 753 | + | (3) a podiatrist, |
|---|
| 754 | + | (4) an optometrist, |
|---|
| 755 | + | (5) a veterinarian, |
|---|
| 756 | + | (6) a physician assistant or Advanced Practice |
|---|
| 757 | + | Registered Nurse under the supervision of a |
|---|
| 758 | + | licensed medical doctor or osteop athic physician, |
|---|
| 759 | + | (7) a scientific investigator, or |
|---|
| 760 | + | (8) any other person, |
|---|
| 761 | + | licensed, registered or otherwise permitted to |
|---|
| 762 | + | prescribe, distribute, dis pense, conduct research with |
|---|
| 763 | + | respect to, use for sci entific purposes or administer |
|---|
| 764 | + | a controlled dangerous subs tance in the course of |
|---|
| 765 | + | professional practice or resea rch in this state, or |
|---|
| 766 | + | b. a pharmacy, hospital, laboratory or other institution |
|---|
| 767 | + | licensed, registered or otherwise permitted to |
|---|
| 768 | + | distribute, dispense, conduct research with respect |
|---|
| 769 | + | |
|---|
| 770 | + | ENGR. H. B. NO. 3073 Page 14 1 |
|---|
| 771 | + | 2 |
|---|
| 772 | + | 3 |
|---|
| 773 | + | 4 |
|---|
| 774 | + | 5 |
|---|
| 775 | + | 6 |
|---|
| 776 | + | 7 |
|---|
| 777 | + | 8 |
|---|
| 778 | + | 9 |
|---|
| 779 | + | 10 |
|---|
| 780 | + | 11 |
|---|
| 781 | + | 12 |
|---|
| 782 | + | 13 |
|---|
| 783 | + | 14 |
|---|
| 784 | + | 15 |
|---|
| 785 | + | 16 |
|---|
| 786 | + | 17 |
|---|
| 787 | + | 18 |
|---|
| 788 | + | 19 |
|---|
| 789 | + | 20 |
|---|
| 790 | + | 21 |
|---|
| 791 | + | 22 |
|---|
| 792 | + | 23 |
|---|
| 793 | + | 24 |
|---|
| 794 | + | |
|---|
| 795 | + | to, use for scientific pu rposes or administer a |
|---|
| 796 | + | controlled dangerous substance in the course of |
|---|
| 797 | + | professional practice o r research in this state; |
|---|
| 798 | + | 33. 34. "Production" includes the manufacture, planting, |
|---|
| 799 | + | cultivation, growing or harvesting of a controlled dange rous |
|---|
| 800 | + | substance; |
|---|
| 801 | + | 34. 35. "State" means the State of Oklahoma or any other s tate |
|---|
| 802 | + | of the United States; |
|---|
| 803 | + | 35. 36. "Ultimate user" means a person who lawfully possesses a |
|---|
| 804 | + | controlled dangerous substance for the person 's own use or for the |
|---|
| 805 | + | use of a member of the person's household or for administration to |
|---|
| 806 | + | an animal owned by the person or by a member of the person's |
|---|
| 807 | + | household; |
|---|
| 808 | + | 36. 37. "Drug paraphernalia" means all equipment, products and |
|---|
| 809 | + | materials of any kind which are used, i ntended for use, or fashioned |
|---|
| 810 | + | specifically for use in plan ting, propagating, cultivating, growing, |
|---|
| 811 | + | harvesting, manufacturing, compounding, converting, p roducing, |
|---|
| 812 | + | processing, preparing, testing, analyzing, packaging, repackaging, |
|---|
| 813 | + | storing, containing, concea ling, injecting, ingesting, inhaling or |
|---|
| 814 | + | otherwise introducing into the human body, a controlled dangerous |
|---|
| 815 | + | substance in violation of the Uniform Controll ed Dangerous |
|---|
| 816 | + | Substances Act inclu ding, but not limited to: |
|---|
| 817 | + | a. kits used, intended for use, or fashioned specifically |
|---|
| 818 | + | for use in planting, pr opagating, cultivating , growing |
|---|
| 819 | + | |
|---|
| 820 | + | ENGR. H. B. NO. 3073 Page 15 1 |
|---|
| 821 | + | 2 |
|---|
| 822 | + | 3 |
|---|
| 823 | + | 4 |
|---|
| 824 | + | 5 |
|---|
| 825 | + | 6 |
|---|
| 826 | + | 7 |
|---|
| 827 | + | 8 |
|---|
| 828 | + | 9 |
|---|
| 829 | + | 10 |
|---|
| 830 | + | 11 |
|---|
| 831 | + | 12 |
|---|
| 832 | + | 13 |
|---|
| 833 | + | 14 |
|---|
| 834 | + | 15 |
|---|
| 835 | + | 16 |
|---|
| 836 | + | 17 |
|---|
| 837 | + | 18 |
|---|
| 838 | + | 19 |
|---|
| 839 | + | 20 |
|---|
| 840 | + | 21 |
|---|
| 841 | + | 22 |
|---|
| 842 | + | 23 |
|---|
| 843 | + | 24 |
|---|
| 844 | + | |
|---|
| 845 | + | or harvesting of any species of plant which is a |
|---|
| 846 | + | controlled dangerous substance or f rom which a |
|---|
| 847 | + | controlled dangerous substance can be derived, |
|---|
| 848 | + | b. kits used, intended for use, or fashioned specifically |
|---|
| 849 | + | for use in manufacturin g, compounding, conver ting, |
|---|
| 850 | + | producing, processing or preparing controlled |
|---|
| 851 | + | dangerous substances, |
|---|
| 852 | + | c. isomerization devices used, intended for use, or |
|---|
| 853 | + | fashioned specifically for use in increasing the |
|---|
| 854 | + | potency of any species of plant which is a controlled |
|---|
| 855 | + | dangerous substance, |
|---|
| 856 | + | d. testing equipment used, intended for use, or fashioned |
|---|
| 857 | + | specifically for use in identifying, or in analyzing |
|---|
| 858 | + | the strength, effectiv eness or purity of controlled |
|---|
| 859 | + | dangerous substances, |
|---|
| 860 | + | e. scales and balances used, intended for use, or |
|---|
| 861 | + | fashioned specifically for use in weighing or |
|---|
| 862 | + | measuring controlled dangerous sub stances, |
|---|
| 863 | + | f. diluents and adulterants, suc h as quinine |
|---|
| 864 | + | hydrochloride, manni tol, mannite, dextrose and |
|---|
| 865 | + | lactose, used, intended for use, or fashione d |
|---|
| 866 | + | specifically for use in cutting co ntrolled dangerous |
|---|
| 867 | + | substances, |
|---|
| 868 | + | |
|---|
| 869 | + | ENGR. H. B. NO. 3073 Page 16 1 |
|---|
| 870 | + | 2 |
|---|
| 871 | + | 3 |
|---|
| 872 | + | 4 |
|---|
| 873 | + | 5 |
|---|
| 874 | + | 6 |
|---|
| 875 | + | 7 |
|---|
| 876 | + | 8 |
|---|
| 877 | + | 9 |
|---|
| 878 | + | 10 |
|---|
| 879 | + | 11 |
|---|
| 880 | + | 12 |
|---|
| 881 | + | 13 |
|---|
| 882 | + | 14 |
|---|
| 883 | + | 15 |
|---|
| 884 | + | 16 |
|---|
| 885 | + | 17 |
|---|
| 886 | + | 18 |
|---|
| 887 | + | 19 |
|---|
| 888 | + | 20 |
|---|
| 889 | + | 21 |
|---|
| 890 | + | 22 |
|---|
| 891 | + | 23 |
|---|
| 892 | + | 24 |
|---|
| 893 | + | |
|---|
| 894 | + | g. separation gins and sifters used, intende d for use, or |
|---|
| 895 | + | fashioned specifically for use in removing twigs and |
|---|
| 896 | + | seeds from, or in otherwise cleaning or refining, |
|---|
| 897 | + | marijuana, |
|---|
| 898 | + | h. blenders, bowls, containers, spoons and mixing dev ices |
|---|
| 899 | + | used, intended for use, or fashioned specifically for |
|---|
| 900 | + | use in compounding controlled dangerous substances, |
|---|
| 901 | + | i. capsules, balloons, envelopes and o ther containers |
|---|
| 902 | + | used, intended for use, or fashioned specifically for |
|---|
| 903 | + | use in packaging small quantities of controlled |
|---|
| 904 | + | dangerous substances, |
|---|
| 905 | + | j. containers and other objects used, inte nded for use, |
|---|
| 906 | + | or fashioned specifically f or use in parenterally |
|---|
| 907 | + | injecting controlled dangerous substances into the |
|---|
| 908 | + | human body, |
|---|
| 909 | + | k. hypodermic syringes, needles and other objects used , |
|---|
| 910 | + | intended for use, or fashioned specifically for use in |
|---|
| 911 | + | parenterally injecting controlled dangerous substances |
|---|
| 912 | + | into the human body, |
|---|
| 913 | + | l. objects used, intended for use, or fashioned |
|---|
| 914 | + | specifically for use in ingesting, inha ling or |
|---|
| 915 | + | otherwise introducing mariju ana, cocaine, hashish or |
|---|
| 916 | + | hashish oil into the human body, such as: |
|---|
| 917 | + | |
|---|
| 918 | + | ENGR. H. B. NO. 3073 Page 17 1 |
|---|
| 919 | + | 2 |
|---|
| 920 | + | 3 |
|---|
| 921 | + | 4 |
|---|
| 922 | + | 5 |
|---|
| 923 | + | 6 |
|---|
| 924 | + | 7 |
|---|
| 925 | + | 8 |
|---|
| 926 | + | 9 |
|---|
| 927 | + | 10 |
|---|
| 928 | + | 11 |
|---|
| 929 | + | 12 |
|---|
| 930 | + | 13 |
|---|
| 931 | + | 14 |
|---|
| 932 | + | 15 |
|---|
| 933 | + | 16 |
|---|
| 934 | + | 17 |
|---|
| 935 | + | 18 |
|---|
| 936 | + | 19 |
|---|
| 937 | + | 20 |
|---|
| 938 | + | 21 |
|---|
| 939 | + | 22 |
|---|
| 940 | + | 23 |
|---|
| 941 | + | 24 |
|---|
| 942 | + | |
|---|
| 943 | + | (1) metal, wooden, acrylic, glass, stone, plasti c or |
|---|
| 944 | + | ceramic pipes with or without screens, permanent |
|---|
| 945 | + | screens, hashish heads or punctured metal bowls, |
|---|
| 946 | + | (2) water pipes, |
|---|
| 947 | + | (3) carburetion tubes and devices, |
|---|
| 948 | + | (4) smoking and carburetion masks, |
|---|
| 949 | + | (5) roach clips, meaning o bjects used to hold burning |
|---|
| 950 | + | material, such as a marijuana cigarette, that has |
|---|
| 951 | + | become too small or too short to be held in the |
|---|
| 952 | + | hand, |
|---|
| 953 | + | (6) miniature cocaine spoons and cocaine vials, |
|---|
| 954 | + | (7) chamber pipes, |
|---|
| 955 | + | (8) carburetor pipes, |
|---|
| 956 | + | (9) electric pipes, |
|---|
| 957 | + | (10) air-driven pipes, |
|---|
| 958 | + | (11) chillums, |
|---|
| 959 | + | (12) bongs, or |
|---|
| 960 | + | (13) ice pipes or chillers, |
|---|
| 961 | + | m. all hidden or novelty pipes, and |
|---|
| 962 | + | n. any pipe that has a tobacco bowl or cham ber of less |
|---|
| 963 | + | than one-half (1/2) inch in diameter in which there is |
|---|
| 964 | + | any detectable residue of any controlled dan gerous |
|---|
| 965 | + | substance as defined in this section or any other |
|---|
| 966 | + | substances not legal for possession or use; |
|---|
| 967 | + | |
|---|
| 968 | + | ENGR. H. B. NO. 3073 Page 18 1 |
|---|
| 969 | + | 2 |
|---|
| 970 | + | 3 |
|---|
| 971 | + | 4 |
|---|
| 972 | + | 5 |
|---|
| 973 | + | 6 |
|---|
| 974 | + | 7 |
|---|
| 975 | + | 8 |
|---|
| 976 | + | 9 |
|---|
| 977 | + | 10 |
|---|
| 978 | + | 11 |
|---|
| 979 | + | 12 |
|---|
| 980 | + | 13 |
|---|
| 981 | + | 14 |
|---|
| 982 | + | 15 |
|---|
| 983 | + | 16 |
|---|
| 984 | + | 17 |
|---|
| 985 | + | 18 |
|---|
| 986 | + | 19 |
|---|
| 987 | + | 20 |
|---|
| 988 | + | 21 |
|---|
| 989 | + | 22 |
|---|
| 990 | + | 23 |
|---|
| 991 | + | 24 |
|---|
| 992 | + | |
|---|
| 993 | + | provided, however, the term "drug paraphernalia" shall not include |
|---|
| 994 | + | separation gins intended for use in preparing tea or spice, clamps |
|---|
| 995 | + | used for constructing electrical equipment, water pipes designed for |
|---|
| 996 | + | ornamentation in which no detectable amount of an illegal substance |
|---|
| 997 | + | is found or pipes designed an d used solely for smoking tobacco, |
|---|
| 998 | + | traditional pipes of an American Indian tribal religious ceremony, |
|---|
| 999 | + | or antique pipes that are thirty (30) years of age or older; |
|---|
| 1000 | + | 37. |
|---|
| 1001 | + | 38. a. "Synthetic controlled substance" means a substance: |
|---|
| 1002 | + | (1) the chemical structure of which is substantially |
|---|
| 1003 | + | similar to the chemical structure o f a controlled |
|---|
| 1004 | + | dangerous substance in Schedule I or I I, |
|---|
| 1005 | + | (2) which has a stimulant, depressant, or |
|---|
| 1006 | + | hallucinogenic effect on the cent ral nervous |
|---|
| 1007 | + | system that is substantially similar to or |
|---|
| 1008 | + | greater than the stimulant, depressant or |
|---|
| 1009 | + | hallucinogenic effect on the central nervous |
|---|
| 1010 | + | system of a controlled dangerous sub stance in |
|---|
| 1011 | + | Schedule I or II, or |
|---|
| 1012 | + | (3) with respect to a particular person, which such |
|---|
| 1013 | + | person represents or intends to have a stimulant, |
|---|
| 1014 | + | depressant, or hallucinogenic effect on the |
|---|
| 1015 | + | central nervous system tha t is substantially |
|---|
| 1016 | + | similar to or greater than the sti mulant, |
|---|
| 1017 | + | |
|---|
| 1018 | + | ENGR. H. B. NO. 3073 Page 19 1 |
|---|
| 1019 | + | 2 |
|---|
| 1020 | + | 3 |
|---|
| 1021 | + | 4 |
|---|
| 1022 | + | 5 |
|---|
| 1023 | + | 6 |
|---|
| 1024 | + | 7 |
|---|
| 1025 | + | 8 |
|---|
| 1026 | + | 9 |
|---|
| 1027 | + | 10 |
|---|
| 1028 | + | 11 |
|---|
| 1029 | + | 12 |
|---|
| 1030 | + | 13 |
|---|
| 1031 | + | 14 |
|---|
| 1032 | + | 15 |
|---|
| 1033 | + | 16 |
|---|
| 1034 | + | 17 |
|---|
| 1035 | + | 18 |
|---|
| 1036 | + | 19 |
|---|
| 1037 | + | 20 |
|---|
| 1038 | + | 21 |
|---|
| 1039 | + | 22 |
|---|
| 1040 | + | 23 |
|---|
| 1041 | + | 24 |
|---|
| 1042 | + | |
|---|
| 1043 | + | depressant, or hallucinogenic effect on the |
|---|
| 1044 | + | central nervous system of a controlled dangerous |
|---|
| 1045 | + | substance in Schedule I or II. |
|---|
| 1046 | + | b. The designation of gamma butyrolactone or any other |
|---|
| 1047 | + | chemical as a precursor, pursuant to Section 2 -322 of |
|---|
| 1048 | + | this title, does not preclude a finding pursuant to |
|---|
| 1049 | + | subparagraph a of this paragraph that the chemical is |
|---|
| 1050 | + | a synthetic controlled substance. |
|---|
| 1051 | + | c. "Synthetic controlled substance" does not include: |
|---|
| 1052 | + | (1) a controlled dangero us substance, |
|---|
| 1053 | + | (2) any substance for which there is an approved new |
|---|
| 1054 | + | drug application, |
|---|
| 1055 | + | (3) with respect to a particular person any |
|---|
| 1056 | + | substance, if an exemption is in effect for |
|---|
| 1057 | + | investigational use, for that person under the |
|---|
| 1058 | + | provisions of Section 505 of the Fed eral Food, |
|---|
| 1059 | + | Drug and Cosmetic Act, Title 21 of the Uni ted |
|---|
| 1060 | + | States Code, Section 355, to the exte nt conduct |
|---|
| 1061 | + | with respect to such subst ance is pursuant to |
|---|
| 1062 | + | such exemption, or |
|---|
| 1063 | + | (4) any substance to the ext ent not intended for |
|---|
| 1064 | + | human consumption before such an exem ption takes |
|---|
| 1065 | + | effect with respect to that substance. |
|---|
| 1066 | + | |
|---|
| 1067 | + | ENGR. H. B. NO. 3073 Page 20 1 |
|---|
| 1068 | + | 2 |
|---|
| 1069 | + | 3 |
|---|
| 1070 | + | 4 |
|---|
| 1071 | + | 5 |
|---|
| 1072 | + | 6 |
|---|
| 1073 | + | 7 |
|---|
| 1074 | + | 8 |
|---|
| 1075 | + | 9 |
|---|
| 1076 | + | 10 |
|---|
| 1077 | + | 11 |
|---|
| 1078 | + | 12 |
|---|
| 1079 | + | 13 |
|---|
| 1080 | + | 14 |
|---|
| 1081 | + | 15 |
|---|
| 1082 | + | 16 |
|---|
| 1083 | + | 17 |
|---|
| 1084 | + | 18 |
|---|
| 1085 | + | 19 |
|---|
| 1086 | + | 20 |
|---|
| 1087 | + | 21 |
|---|
| 1088 | + | 22 |
|---|
| 1089 | + | 23 |
|---|
| 1090 | + | 24 |
|---|
| 1091 | + | |
|---|
| 1092 | + | d. Prima facie evidence that a substance co ntaining |
|---|
| 1093 | + | salvia divinorum has been en hanced, concentrated or |
|---|
| 1094 | + | chemically or physically altered shall give rise to a |
|---|
| 1095 | + | rebuttable presumption th at the substance is a |
|---|
| 1096 | + | synthetic controlled substance; |
|---|
| 1097 | + | 38. 39. "Tetrahydrocannabinols" means all substances that have |
|---|
| 1098 | + | been chemically synthesized to emulate the tetrahydrocannabinols of |
|---|
| 1099 | + | marijuana; |
|---|
| 1100 | + | 39. 40. "Isomer" means the optical isomer, except as used in |
|---|
| 1101 | + | subsections C and F of Section 2-204 of this title and paragraph 4 |
|---|
| 1102 | + | of subsection A of Section 2-206 of this title. As used in |
|---|
| 1103 | + | subsections C and F of Section 2-204 of this title, "isomer" means |
|---|
| 1104 | + | the optical, positional or geometric isomer. As used in paragraph 4 |
|---|
| 1105 | + | of subsection A of Section 2-206 of this title, the term "isomer" |
|---|
| 1106 | + | means the optical or geometric isomer; |
|---|
| 1107 | + | 40. 41. "Hazardous materials" means materials, whether solid, |
|---|
| 1108 | + | liquid or gas, which are toxic to human, a nimal, aquatic or plant |
|---|
| 1109 | + | life, and the disposal of which ma terials is controlled by state or |
|---|
| 1110 | + | federal guidelines; |
|---|
| 1111 | + | 41. 42. "Anhydrous ammonia" means any substance that exhibits |
|---|
| 1112 | + | cryogenic evaporative behavio r and tests positive for ammonia; |
|---|
| 1113 | + | 42. 43. "Acute pain" means pain, whether resulting fr om |
|---|
| 1114 | + | disease, accidental or intentional trauma or other cause, that the |
|---|
| 1115 | + | practitioner reasonably expects to las t only a short period of time . |
|---|
| 1116 | + | |
|---|
| 1117 | + | ENGR. H. B. NO. 3073 Page 21 1 |
|---|
| 1118 | + | 2 |
|---|
| 1119 | + | 3 |
|---|
| 1120 | + | 4 |
|---|
| 1121 | + | 5 |
|---|
| 1122 | + | 6 |
|---|
| 1123 | + | 7 |
|---|
| 1124 | + | 8 |
|---|
| 1125 | + | 9 |
|---|
| 1126 | + | 10 |
|---|
| 1127 | + | 11 |
|---|
| 1128 | + | 12 |
|---|
| 1129 | + | 13 |
|---|
| 1130 | + | 14 |
|---|
| 1131 | + | 15 |
|---|
| 1132 | + | 16 |
|---|
| 1133 | + | 17 |
|---|
| 1134 | + | 18 |
|---|
| 1135 | + | 19 |
|---|
| 1136 | + | 20 |
|---|
| 1137 | + | 21 |
|---|
| 1138 | + | 22 |
|---|
| 1139 | + | 23 |
|---|
| 1140 | + | 24 |
|---|
| 1141 | + | |
|---|
| 1142 | + | "Acute pain" does not include chronic pain, pain being treated as |
|---|
| 1143 | + | part of cancer care, hospice or other end-of-life care, or pain |
|---|
| 1144 | + | being treated as part of palliative care; |
|---|
| 1145 | + | 43. 44. "Chronic pain" means pain that persists beyond the |
|---|
| 1146 | + | usual course of an acute disease or healing of an in jury. "Chronic |
|---|
| 1147 | + | pain" may or may not be associated w ith an acute or chronic |
|---|
| 1148 | + | pathologic process that causes con tinuous or intermittent pain over |
|---|
| 1149 | + | months or years; |
|---|
| 1150 | + | 44. 45. "Initial prescription" means a prescription issued to a |
|---|
| 1151 | + | patient who: |
|---|
| 1152 | + | a. has never previously been issued a prescription for |
|---|
| 1153 | + | the drug or its pharmaceutical equivalent in the p ast |
|---|
| 1154 | + | year, or |
|---|
| 1155 | + | b. requires a prescription for the drug or its |
|---|
| 1156 | + | pharmaceutical equivalent due to a surgical procedur e |
|---|
| 1157 | + | or new acute event and has previously had a |
|---|
| 1158 | + | prescription for the drug or its pharmaceutical |
|---|
| 1159 | + | equivalent within the past year. |
|---|
| 1160 | + | When determining whether a patient was previously issued a |
|---|
| 1161 | + | prescription for a drug or its ph armaceutical equivalent, the |
|---|
| 1162 | + | practitioner shall consult with the patient and review the medic al |
|---|
| 1163 | + | record and prescription monitoring information of the patient; |
|---|
| 1164 | + | 45. 46. "Patient-provider agreement" means a written contract |
|---|
| 1165 | + | or agreement that is executed betw een a practitioner and a patient, |
|---|
| 1166 | + | |
|---|
| 1167 | + | ENGR. H. B. NO. 3073 Page 22 1 |
|---|
| 1168 | + | 2 |
|---|
| 1169 | + | 3 |
|---|
| 1170 | + | 4 |
|---|
| 1171 | + | 5 |
|---|
| 1172 | + | 6 |
|---|
| 1173 | + | 7 |
|---|
| 1174 | + | 8 |
|---|
| 1175 | + | 9 |
|---|
| 1176 | + | 10 |
|---|
| 1177 | + | 11 |
|---|
| 1178 | + | 12 |
|---|
| 1179 | + | 13 |
|---|
| 1180 | + | 14 |
|---|
| 1181 | + | 15 |
|---|
| 1182 | + | 16 |
|---|
| 1183 | + | 17 |
|---|
| 1184 | + | 18 |
|---|
| 1185 | + | 19 |
|---|
| 1186 | + | 20 |
|---|
| 1187 | + | 21 |
|---|
| 1188 | + | 22 |
|---|
| 1189 | + | 23 |
|---|
| 1190 | + | 24 |
|---|
| 1191 | + | |
|---|
| 1192 | + | prior to the commencement of treatment for chronic pain usi ng an |
|---|
| 1193 | + | opioid drug as a means to: |
|---|
| 1194 | + | a. explain the possible risk of development of physical |
|---|
| 1195 | + | or psychological depe ndence in the patient and prevent |
|---|
| 1196 | + | the possible development of addiction, |
|---|
| 1197 | + | b. document the understanding of both the practitioner |
|---|
| 1198 | + | and the patient regarding the patient-provider |
|---|
| 1199 | + | agreement of the patien t, |
|---|
| 1200 | + | c. establish the rights of the pa tient in association |
|---|
| 1201 | + | with treatment and the obligations of the patient in |
|---|
| 1202 | + | relation to the responsible use, disc ontinuation of |
|---|
| 1203 | + | use, and storage of opioid drugs, includin g any |
|---|
| 1204 | + | restrictions on the refill of prescriptions or the |
|---|
| 1205 | + | acceptance of opioid prescripti ons from practitioners , |
|---|
| 1206 | + | d. identify the specific medications and other mode s of |
|---|
| 1207 | + | treatment, including physical therapy or exercise, |
|---|
| 1208 | + | relaxation or psychological counselin g, that are |
|---|
| 1209 | + | included as a part of the patient-provider agreement, |
|---|
| 1210 | + | e. specify the measures the practitioner may employ to |
|---|
| 1211 | + | monitor the compliance of the patient incl uding, but |
|---|
| 1212 | + | not limited to, random specimen screens and pill |
|---|
| 1213 | + | counts, and |
|---|
| 1214 | + | f. delineate the process for terminating the agreement, |
|---|
| 1215 | + | including the consequences if the practitioner has |
|---|
| 1216 | + | |
|---|
| 1217 | + | ENGR. H. B. NO. 3073 Page 23 1 |
|---|
| 1218 | + | 2 |
|---|
| 1219 | + | 3 |
|---|
| 1220 | + | 4 |
|---|
| 1221 | + | 5 |
|---|
| 1222 | + | 6 |
|---|
| 1223 | + | 7 |
|---|
| 1224 | + | 8 |
|---|
| 1225 | + | 9 |
|---|
| 1226 | + | 10 |
|---|
| 1227 | + | 11 |
|---|
| 1228 | + | 12 |
|---|
| 1229 | + | 13 |
|---|
| 1230 | + | 14 |
|---|
| 1231 | + | 15 |
|---|
| 1232 | + | 16 |
|---|
| 1233 | + | 17 |
|---|
| 1234 | + | 18 |
|---|
| 1235 | + | 19 |
|---|
| 1236 | + | 20 |
|---|
| 1237 | + | 21 |
|---|
| 1238 | + | 22 |
|---|
| 1239 | + | 23 |
|---|
| 1240 | + | 24 |
|---|
| 1241 | + | |
|---|
| 1242 | + | reason to believe that t he patient is not complying |
|---|
| 1243 | + | with the terms of the agr eement. Compliance with the |
|---|
| 1244 | + | "consent items" shall constitute a valid, informed |
|---|
| 1245 | + | consent for opioid therapy. The practitioner shall be |
|---|
| 1246 | + | held harmless from civil litigation for failur e to |
|---|
| 1247 | + | treat pain if the event occurs because of nonadherence |
|---|
| 1248 | + | by the patient with any of the provisions of the |
|---|
| 1249 | + | patient-provider agreement; |
|---|
| 1250 | + | 46. 47. "Serious illness" means a medical illness o r physical |
|---|
| 1251 | + | injury or condition that substantially affects quality o f life for |
|---|
| 1252 | + | more than a short period of time . "Serious illness" includes, but |
|---|
| 1253 | + | is not limited to, Alzheimer 's disease or related dementias, lung |
|---|
| 1254 | + | disease, cancer, heart f ailure, renal failure , liver failure or |
|---|
| 1255 | + | chronic, unremitting or intractable pain such as neuropathic pain; |
|---|
| 1256 | + | and |
|---|
| 1257 | + | 47. 48. "Surgical procedure" means a procedure that is |
|---|
| 1258 | + | performed for the purpose of struct urally altering the human body by |
|---|
| 1259 | + | incision or destruct ion of tissues as part of the practice of |
|---|
| 1260 | + | medicine. This term includes the diagnostic o r therapeutic |
|---|
| 1261 | + | treatment of conditions or disease processes by use of instru ments |
|---|
| 1262 | + | such as lasers, ultrasound, ioniz ing, radiation, scalpels, probes or |
|---|
| 1263 | + | needles that cause localized alteration or transportation of live |
|---|
| 1264 | + | human tissue by cutting, burning, vapori zing, freezing, suturi ng, |
|---|
| 1265 | + | probing or manipulating by closed reduction for m ajor dislocations |
|---|
| 1266 | + | |
|---|
| 1267 | + | ENGR. H. B. NO. 3073 Page 24 1 |
|---|
| 1268 | + | 2 |
|---|
| 1269 | + | 3 |
|---|
| 1270 | + | 4 |
|---|
| 1271 | + | 5 |
|---|
| 1272 | + | 6 |
|---|
| 1273 | + | 7 |
|---|
| 1274 | + | 8 |
|---|
| 1275 | + | 9 |
|---|
| 1276 | + | 10 |
|---|
| 1277 | + | 11 |
|---|
| 1278 | + | 12 |
|---|
| 1279 | + | 13 |
|---|
| 1280 | + | 14 |
|---|
| 1281 | + | 15 |
|---|
| 1282 | + | 16 |
|---|
| 1283 | + | 17 |
|---|
| 1284 | + | 18 |
|---|
| 1285 | + | 19 |
|---|
| 1286 | + | 20 |
|---|
| 1287 | + | 21 |
|---|
| 1288 | + | 22 |
|---|
| 1289 | + | 23 |
|---|
| 1290 | + | 24 |
|---|
| 1291 | + | |
|---|
| 1292 | + | or fractures, or othe rwise altering by any mechanical, thermal, |
|---|
| 1293 | + | light-based, electromagnetic or chem ical means. |
|---|
| 1294 | + | SECTION 2. AMENDATORY 63 O. S. 2021, Section 2-309I, is |
|---|